← Back to guidelines
Pathology277 papers

Adenocarcinoma in situ

Last edited: 4/14/2026

Overview

Adenocarcinoma in situ (AIS) is a precancerous lesion characterized by neoplastic cells confined to the basement membrane without invasion into underlying stroma, posing diagnostic challenges particularly in cytology 1.

Diagnosis

  • Cytologic Diagnosis: Difficult to accurately interpret on Papanicolaou (Pap) smears with a false-negative rate of 6.9% 1.
  • Comparison of Techniques: ThinPrep (TP) showed lower accuracy (47%) compared to Pap smear (67%) in predicting AIS, though TP has potential with further slides 2.
  • Histopathology: Essential for definitive diagnosis; external quality assurance schemes highlight variability in scoring but are crucial for maintaining standards 3.
  • Management

  • Surgical Management: Often involves excisional procedures such as hysterectomy or local excision, though specific drug treatments are not detailed in provided abstracts.
  • Follow-Up: Regular monitoring post-treatment is critical to detect any recurrence or progression 1.
  • Special Populations

  • No Specific Guidance: The provided abstracts do not offer detailed recommendations specific to pregnancy, pediatrics, elderly patients, or comorbidities 1234.
  • Key Recommendations

  • Utilize ThinPrep technology cautiously, recognizing its potential but current limitations in accurately predicting AIS compared to traditional Pap smears (Evidence: Moderate 2).
  • Implement rigorous external quality assurance programs in histopathology to maintain diagnostic accuracy and consistency (Evidence: Strong 3).
  • Employ histopathology for definitive diagnosis of AIS due to the challenges in cytologic interpretation (Evidence: Strong 1).
  • References

    1 Zhao C, Crothers BA, Tabatabai ZL, Li Z, Ghofrani M, Souers RJ et al.. False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program. Archives of pathology & laboratory medicine 2017. link 2 Roberts JM, Thurloe JK, Bowditch RC, Humcevic J, Laverty CR. Comparison of ThinPrep and Pap smear in relation to prediction of adenocarcinoma in situ. Acta cytologica 1999. link 3 Klys HS, Lessells AM. External quality assurance in histopathology: experience of the east of Scotland scheme. Journal of clinical pathology 1992. link 4 Ramsay AD. Locally organised medical audit in histopathology. Journal of clinical pathology 1991. link

    Original source

    1. [1]
      False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program.Zhao C, Crothers BA, Tabatabai ZL, Li Z, Ghofrani M, Souers RJ et al. Archives of pathology & laboratory medicine (2017)
    2. [2]
      Comparison of ThinPrep and Pap smear in relation to prediction of adenocarcinoma in situ.Roberts JM, Thurloe JK, Bowditch RC, Humcevic J, Laverty CR Acta cytologica (1999)
    3. [3]
      External quality assurance in histopathology: experience of the east of Scotland scheme.Klys HS, Lessells AM Journal of clinical pathology (1992)
    4. [4]
      Locally organised medical audit in histopathology.Ramsay AD Journal of clinical pathology (1991)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG